Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220011306IMMUNOCHROMATOGRAPHIC TEST STRIP AND IMMUNOCHROMATOGRAPHIC DETECTION KIT
US 13.01.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No 17294183 Applicant SEKISUI MEDICAL CO., LTD. Inventor Keigo KOHNO

A problem to be solved is to provide an immunochromatographic test strip in which a specimen sufficiently and quickly permeates into a sample application region within a test time so that variations in detection values of a test line can be prevented. Particularly, a problem to be solved is to provide an immunochromatographic test strip causing less variations in detection values even when the specimen is whole blood.

The problems are solved by providing an immunochromatographic test strip including at least a sample application region, a development region, and a detection region, wherein the sample application region contains polyethylene glycol having a molecular weight of 15,000 to 700,000.

2.WO/2022/007251NANO-PLASMON RESONANCE-BASED QUANTITATIVE DETECTION METHOD FOR NOVEL CORONAVIRUS PARTICLES
WO 13.01.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/CN2020/123839 Applicant LIANGZHUN (SHANGHAI) MEDICAL EQUIPMENT CO., LTD. Inventor HUANG, Li Ping
A nano-plasmon resonance-based quantitative detection method for novel coronavirus particles, comprising: preparing a plasmon resonance coupling effect device (S1) and preparing gold nanoparticles used for amplifying detection signals (S2); modifying a SARS‑COV‑2 capture antibody on the surface of a nano-plasmon resonance sensor chip (S3), and labeling the gold nanoparticles by using a SARS‑COV‑2 labeled antibody (S4); adding SARS‑CoV‑2 virus particle samples of different titers to the labeled gold nanoparticles (S5); adding a mixed solution to an orifice plate to be tested to complete the capture of a SARS-CoV-2 virus particle and labeled nano-gold particle complex (S6); and by means of detecting the change curve of the differences over time in absorbance at a specific wavelength before and after sample addition, quantitatively detecting SARS-CoV-2 virus particles (S7).
3.20220011316LIQUID TESTING SYSTEM, DEVICES, AND METHODS
US 13.01.2022
Int.Class G01N 33/58
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
58involving labelled substances
Appl.No 17360219 Applicant Johan M. SPOOR Inventor Johan M. SPOOR

A testing system and test cartridge for analyzing a sample of water from a water source for specific analyte levels. The test cartridge including a membrane filter that captures a target analyte while allowing a labelled conjugate to permeate through the membrane. The conjugate includes an analyte-specific labelled binding reagent to bind with the target analyte for optical detection. The direct membrane interrogation (i.e., on-filter detection), determines analyte levels without elution of the analyte from a filter thereby improving analyte recovering and assay sensitivity.

4.WO/2022/010353METHODS FOR IDENTIFYING CORONAVIRUS CROSS-REACTING ANTIBODIES
WO 13.01.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/NL2021/050435 Applicant LEYDEN LABORATORIES B.V. Inventor GOUDSMIT, Jaap
The disclosure provides methods for identifying coronavirus cross-reacting antibodies. Such antibodies bind to at least part of the S2 ectodomain of the S protein of at least one common human coronavirus selected from HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1 and bind to at least part of the S2 ectodomain of the S protein of at least one highly pathogenic human coronavirus selected from SARS-CoV- 1, MERS-CoV and SARS-CoV-2. Antibodies identified by the methods described herein are particularly useful for treating or preventing coronaviral infections, in particular against highly pathogenic coronaviruses such as SARS-CoV-1, MERS-CoV and/or SARS-CoV-2 as well as cross-species transmission of typically non-human coronaviruses.
5.WO/2022/008479CD1 PEPTIDE-EPITOPE FOR USE IN THE TREATMENT OF A DISEASE CAUSED BY AN INTRACELLULAR PATHOGEN
WO 13.01.2022
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/EP2021/068585 Applicant IMNATE SARL Inventor SAINT-REMY, Jean-Marie
A CD1 peptide-epitope for use in the treatment of a disease causedby an intracellular pathogen, the method for the identification ofthis CD1 peptide epitope, the pharmaceutical kit comprising thisCD1 peptide epitope and the method to treat a patient against adisease caused by an intracellular pathogen or to prevent suchinfection, based on vaccination with this CD1 peptide-epitope.
6.WO/2022/009034CARBON-ENCAPSULATED MYCOLIC ACID ANTIGENS AS SIMPLE AND LOW-COST ELECTROCHEMICAL IMMUNOSENSORS FOR ACTIVE TUBERCULOSIS
WO 13.01.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/IB2021/055906 Applicant UNIVERSITY OF PRETORIA Inventor OZOEMENA, Kenneth, Ikechukwu
The invention is directed at a method of encapsulating mycolic acid antigen in carbon, wherein carbon and mycolic acid antigen are dissolved in solution, the solution is ultrasonicated, and dried. The invention is also directed to a carbon-encapsulated mycolic acid antigen produced by this method for use as an electrochemical immunosensor for detection of tuberculosis by detecting presence of mycolic acid antibodies in a serum sample.
7.20220009970IMMUNOGENIC COMPOSITION AGAINST AVIAN INFLUENZA VIRUS H5 SUBTYPE
US 13.01.2022
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 17291924 Applicant BOEHRINGER INGELHEIM VETMEDICA GMBH Inventor Egbert Siegfried MUNDT

The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.

8.WO/2022/011285AUTOMATED SAMPLE PREPARATION PLATFORM FOR CELLULAR ANALYSIS
WO 13.01.2022
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/US2021/041123 Applicant BECKMAN COULTER, INC. Inventor BOUVIER, Gaelle
The disclosure relates to, among other things, an automated flow cytometric method and system for the analysis and enumeration of at least one of hematopoietic stem cells, hematopoietic progenitor cells, and T-cells.
9.20220011293METHOD AND DEVICES FOR DETECTING VIRUSES AND BACTERIAL PATHOGENS
US 13.01.2022
Int.Class G01N 33/487
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
487of liquid biological material
Appl.No 17324085 Applicant Matthew Hummer Inventor Matthew Hummer

The embodiments disclose a method including functionalizing a biosensor with a biologic analytical target prior to installation into a detection cartridge, depositing a test subject bodily fluid test sample onto the biosensor surface, inserting the detection cartridge into a portable detection cartridge reader, measuring the electrical impedance of the bodily fluid test sample across biosensor energized electrodes, providing algorithms for analyzing measured electrical impedance data of the bodily fluid test sample obtained in the detection cartridge, identifying and determining the presence of biologic analytical target molecules in the bodily fluid test sample, and transmitting results of the test results to the test subject.

10.20220011304BIOSENSOR AND METHOD FOR DETECTION OF ANALYTES
US 13.01.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No 17297385 Applicant UNIVERSITY OF NOTRE DAME DU LAC Inventor Jiayun Hu

Described is a biosensor for detection of analytes and methods of using the same for detecting bacterial infection in a subject. The biosensor comprises an array of gold nanoparticles, biotinylated polyethylene glycol thiol, polyethylene glycol thiol, at least one neutravidin molecule, and at least one affinity reagent immobilized on a surface of the at least one neutravidin molecule. The affinity reagent may be an aptamer or a siderophore. The biosensors demonstrate extraordinary selectively and sensitivity for rapid detection of whole-cell bacteria.